Objective-This report demonstrates the utility of linking the restricted-use 2014 National Hospital Care Survey (NHCS), 2014-2015 National Death Index (NDI), and 2014-2015 Drug-Involved Mortality (DIM) data to study opioid-involved emergency department (ED) visits, hospitalizations, and mortality within 1 year post-discharge. Example research questions and unweighted results are presented. Results are not nationally representative. Methods-Patient records from the 2014 NHCS with sufficient identifying information were linked to the 2014-2015 NDI and DIM data. Visits were considered opioid-involved if they had International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes 304.00-304.02, 304.70-304.72, 305.50-305.52, 760.72, 965.00-965.02, 965.09, 970.1, or E850.0-E850.2 in any diagnosis or external cause of injury code field. Opioid-involved drug overdose deaths were deaths with an International Classification of Diseases, 10th Revision (ICD-10) underlying cause-of-death code of X40-44, X60-64, X85, or Y10-Y14 and a multiple cause code of T40.0-T40.4 or T40.6. Results-In the 2014 NHCS, there were 15,495 patients with an opioid-involved ED-only visit and 24,059 patients with an opioid-involved hospitalization. Of the 20,962 patients with an opioid-involved hospitalization eligible to be linked to NDI, 1,805 died (9%) within 1 year of discharge. Of these deaths, 341 (19%) resulted from a drug overdose. Of drug overdose deaths, 243 (71%) involved an opioid, where 12% died within 30 days post-discharge, 19% within 31-90 days, and 69% within 91-365 days. Opioids most frequently mentioned included heroin (46%), fentanyl (20%), oxycodone (13%), methadone (12%), and morphine (12%). These categories are not mutually exclusive because a death may involve more than one drug. For approximately 22% of patients who died of an opioid-involved drug overdose in 2014, their last ED-only visit or hospitalization was opioid-involved. Conclusion-While the NHCS data are not nationally representative, these unlinked and linked National Center for Health Statistics data allow for exploratory analyses of ED visits, hospitalizations, and associated mortality outcomes.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Categorizing Stigma as a Barrier to Support Following Nonfatal Overdose: A Qualitative Study.
J Addict Med
January 2025
From the Boonshoft School of Medicine, Wright State University, Dayton, OH (KL, SS, TNC); Ohio State University, Columbus, OH (SH, NM, TP); and RTI International, Research Triangle Park, NC (BR).
Objectives: Stigma is known to be a major barrier to treatment for people who use drugs (PWUD). This study uses the Stigma and Health Discrimination Framework to analyze how different forms of stigma shape experiences in the wake of an overdose incident, and perceptions of the efficacy and utility of postoverdose interventions among a sample of PWUD in Dayton, Ohio-a location with a high overdose rate.
Methods: Interviews were conducted with 23 individuals who self-reported past-month illicit opioid, crack/cocaine, or methamphetamine use who had experienced or witnessed a drug overdose in the past 6 months.
Listings of Buprenorphine Offering by Substance Use Disorder Treatment Facilities and Waivered Clinician From July 2019 to May 2021.
J Addict Med
January 2025
From the Department of Health Policy and Management, University of Maryland, College Park, MD (MMA); RAND, Santa Monica, CA (EAT, YM, DA, JC); and RAND, Pittsburgh, PA (BDS).
Objectives: This study explores trends in buprenorphine availability at substance use disorder treatment facilities (SUDTFs) and by waivered clinicians during the pandemic. We also examined whether there were differences in access based on a county's metropolitan status and annual fatal drug poisoning rate.
Methods: Data from the Substance Abuse and Mental Health Services Administration' Behavioral Health Treatment Locator between July 2019 and May 2021 were used to calculate trends in SUDTFs offering buprenorphine and the number of waivered clinicians per 10,000 population.
Cost-Effective Drug Testing: Analytical Methodology, Best Practices, and Clinical Utility.
J Appl Lab Med
January 2025
Department of Pathology and Laboratory Medicine, UC Davis Health, Sacramento, CA, United States.
Background: Drug overdose-related deaths continue to increase globally. Testing demands have likewise increased, prompting healthcare facilities to adopt a range of methods, from simple point-of-care immunoassays to comprehensive chromatographic and mass spectrometry-based techniques. Each of these testing methods has trade-offs related to cost, performance, speed, and convenience, requiring healthcare facilities to carefully determine the best options to meet their clinical needs.
View Article and Find Full Text PDFA Cross-Sectional Evaluation of Opioid Dispensing Competencies in Final-Year Pharm-D Students: A Multicenter Study from Punjab, Pakistan.
Drug Healthc Patient Saf
December 2024
Pharmacology and Therapeutics, University Medical & Dental College, the University of Faisalabad, University of Birmingham, Birmingham, UK.
Background: The opioid crisis continues to be a public health concern worldwide due to the high rates of misuse and associated mortality. Opioid dispensing competencies are critical for pharmacy graduates to promote the rational use of opioids.
Purpose: To evaluate the opioids dispensing competencies among the final year Pharm-D students in Punjab, Pakistan.
Public health implications of recent declines in fatal drug overdoses in New York State and the United States.
Health Aff Sch
December 2024
New York State Department of Health, Office of the Commissioner, Albany, NY 12237, United States.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!